Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Assets (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Current Assets for 6 consecutive years, with $975.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 5.59% to $975.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $975.9 million through Dec 2025, down 5.59% year-over-year, with the annual reading at $975.9 million for FY2025, 5.59% down from the prior year.
  • Current Assets for Q4 2025 was $975.9 million at Janux Therapeutics, down from $998.1 million in the prior quarter.
  • The five-year high for Current Assets was $1.0 billion in Q4 2024, with the low at $309.3 million in Q2 2023.
  • Average Current Assets over 5 years is $574.8 million, with a median of $389.6 million recorded in 2021.
  • The sharpest move saw Current Assets soared 2247.27% in 2021, then dropped 13.62% in 2023.
  • Over 5 years, Current Assets stood at $377.0 million in 2021, then dropped by 11.82% to $332.4 million in 2022, then increased by 5.05% to $349.2 million in 2023, then soared by 195.97% to $1.0 billion in 2024, then dropped by 5.59% to $975.9 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $975.9 million, $998.1 million, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.